Bio-distribution study of Tc-99m HMPAO labeled platelet in healthy volunteer

Document Type : Original Article

Authors

1 Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

3 Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany

4 Department of Neurology, School of Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

5 Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Objective(s): The bio-distribution of Tc-99m HMPAO labeled platelets (LP), which could be used to image subtle thrombosis, is not reported in a human yet, which is the subject of the current study.
Method: The platelets were extracted from 49 ml whole blood and labeled with Tc-99m HMPAO, then re-injected to the healthy volunteer. Anterior and posterior whole body imaging was done by a dual-head gamma camera 3, 18, 33, 46, 81, 124, 190 min and 15 hours after injection. Also a whole-body SPECT was done at 137 min post-injection. The area under the curves of the spleen, liver, left kidney, bladder, right lung, brain, and abdominal aorta ROIs was calculated to estimate the accumulation of labeled platelets within the organs.
Results: The spleen was the target organ. The kidneys, liver, and heart were also remarkably visualized. The thyroid, stomach, bladder, or gastrointestinal (GI) uptake/activity was not significant. The stomach visualization was enhanced after ingestion at 60 min. The sagittal and lateral sinuses were delineated, and the background of the brain was very low. During the study, the area under the curve of activity was 738, 308, 302, 196, 230, 121, 79, 216, 529, 369, 162, and 54 counts. min/pixel for spleen, liver, heart, right lung, left kidney, right iliac artery, sagittal sinus, thyroid, bladder, stomach, GI, and background, respectively.
Conclusion: The quality of the scan with low dose Tc-99m HMPAO LPs is optimal. We documented the bio-distribution of LPs. The optimal imaging time was 80-120 min post-injection when the free Tc-99m and GI transit were negligible. The sagittal and lateral sinuses were visualized enabling detection of possible clots in the vessels.

Keywords

Main Subjects

References

  1. Tsimikas S, Shortal BP, Witztum JL, Palinski W. In vivo uptake of radio labeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler Thromb Vasc Biol 2000; 20: 689-697.
  2. Cerqueira MD, Stratton JR, Vracko R, Schaible TF, Ritchie JL. Noninvasive arterial thrombus imaging with 99mTc monoclonal antifibrin antibody. Circulation 1992; 85:298-304.
  3. Fang W, He J, Kim Y-S, Zhou Y, Liu S. Evaluation of 99mTc-labeled cyclic RGD peptide with a PEG4 linker for thrombosis imaging: comparison with DMP444. Bioconjug Chem 2011; 22:1715-1722.
  4. Zhou Y, Chakraborty S, Liu S. Radiolabeled cyclic RGD peptides as radiotracers for imaging tumors and thrombosis by SPECT. Theranostics 2011; 1:58.
  5. Rodrigues M, Sinzinger H, Thakur M, Becker W, Dewanjee M, Ezekowitz M, et al. labelling of platelets with indium-111 oxine and technetium-99m hexa methyl propylene amine oxime: suggested methods. Eur J Nucl Med Mol Imaging 1999; 26:1614-1616.
  6. Prats E, Civeira E, Abos MD, Garcia-Lopez F, Banzo J. Tc-99m HMPAO labeled platelets in the detection of left ventricular thrombosis post-acute myocardial infarction. Clin Nucl Med 1996; 21:864-866.
  7. Dewanjee MK, Kapadvanjwala M, Ruzius K, Serafini AN, Zilleruelo GE, Sfakianakis GN. Quantitation of thrombogenicity of hemo dialyzer with technetium-99m and indium-111 labelled platelets. NUCL MED BIOL 1993; 20:579-587.
  8. Vorne M, Honkanen T, Lantto T, Laitinen R, Karppinen K, Jauhola S. Thrombus imaging with 99mTc-HMPAO-labeled platelets and 111In-labeled monoclonal antifibrin antibodies. Acta radiol 1993; 34:59-63.
  9. Honkanen T, Jauhola S, Karppinen K, Paul R, Sakki S, Vorne M. Venous thrombosis: A controlled study on the performance of scintigraphy with 99mTc-HMPAO-labelled platelets versus venography. Nucl Med Commun 1992; 13:88-94.
  10. Hardeman M. Thrombocytes labelled with 99mTc-HMPAO in vitro studies and preliminary clinical experience. Prog Clin Biol Res 1990; 355:49-54.
  11. Becker W, Borst U, Krahe T, Börner W. Tc-99m-HMPAO labelled human platelets: in vitro and in vivo results. Eur. J Nucl Med 1989; 15:296-301.
  12. Becker W, Börner W, Borst U. 99mTc hexa methyl propylene amine oxime (HMPAO) as a platelet label: evaluation of labelling parameters and first in vivo results. Nucl Med Commun 1988; 9:831-842.
  13. Danpure H, Osman S. Investigations to determine the optimum conditions for radiolabelling human platelets with 99mTc-hexamethyl propylene amine oxime (99mTc-HMPAO). Nucl Med Commun 1988; 9:267-272.
  14. Thakur ML, Welch MJ, Joist JH, Coleman RE. Indium-111 labelled platelets: studies on preparation and evaluation of in vitro and in vivo functions. Thromb Res 1976; 9:345-357.
  15. Vorne M, Honkanen T, Karppinen K, Röning M, Sakki S. Radiolabelling of human platelets with 99mTc‐HMPAO. Eur J Haematol 1989; 42:487-491.
  16. De Vries EF, Roca M, Jamar F, Israel O, Signore A. Guidelines for the labelling of leucocytes with 99mTc-HMPAO. Eur J Nucl Med Mol Imaging 2010; 37:842-848.
  17. Parvizi M, Farzanefar S, Khalaj A, Tafakhori A, Daha FJ, Saffar H, Sadeghzadeh M, Naseri M, Ahmadzadehfar H, Abbasi M. 99m Technetium-HMPAO-labeled platelet scan in practice: Preparation, quality control, and biodistribution studies. Brazilian Journal of Pharmaceutical Sciences. 2022; 18:58.
  18. Parvizi M, Farzanefar S, Tafakhori A, Gholami M, Daha FJ, Saffar H, Khalaj A, Abbasi M. Imaging of clot by 99mTc-HMPAO labeled platelet in animal model induced thrombosis. Iran J Pharm Re: IJPR. 2020;19(4):76. S.
  19. Davidson BL, Elliott CG, Lensing AW. Low accuracy of color Doppler ultrasound in the detection of proximal leg vein thrombosis in asymptomatic high-risk patients. Ann Intern Med1992; 117:735-735.
  20. Loud PA, Katz DS, Bruce DA, Klippenstein DL, Grossman ZD. Deep venous thrombosis with suspected pulmonary embolism: detection with combined CT venography and pulmonary angiography. Radiology 2001; 219:498-502.
  21. Meaney JF, Weg JG, Chenevert TL, Stafford-Johnson D, Hamilton BH, Prince MR. Diagnosis of pulmonary embolism with magnetic resonance angiography. N Engl J Med 1997; 336:1422-1427.
  22. Gandhi SJ, Babu S, Subramanyam P, Sundaram PS. Tc-99m macro aggregated albumin scintigraphy–indications other than pulmonary embolism: A pictorial essay. Indian journal of nuclear medicine: IJNM: the official journal of the Society of Nuclear Medicine, India 2013; 28:152.
  23. Peters A, Lavender J, Needham S, Loutfi I, Snook D, Epenetos A, et al. Imaging thrombus with radiolabelled monoclonal antibody to platelets. Br Med J (Clin Res Ed) 1986; 293:1525-1527.
  24. Saposnik G, Barinagarrementeria F, Brown RD, Bushnell CD, Cucchiara B, Cushman M, et al. Diagnosis and management of cerebral venous thrombosis. Stroke: STR. 0b013e31820a 38364 2011.
  25. Rowe S, Hawkins B, Hamilton L, Seaton BC, Buzzeo M, Henry J, et al. 725: Contrast- induced nephropathy in stroke patients undergoing CT angiography: Cinicter study. Crit Care Med 2016; 44:257.
  26. Botnar RM, Perez AS, Witte S, Wiethoff AJ, Laredo J, Hamilton J, et al. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation 2004; 109:2023-2029.
  27. Houshmand S, Salavati A, Hess S, Ravina M, Alavi A. The role of molecular imaging in diagnosis of deep vein thrombosis. Am J Nucl Med Mol Imaging 2014; 4:406. 
Asia Oceania Journal of Nuclear Medicine and Biology
Volume 12, Issue 2
July 2024
Pages 142-148

Files

Share

How to cite

Statistics